1.43

0.00% 0.00

Acurx Pharmaceuticals Inc (ACXP)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.43

Offen:

$1.4127

24-Stunden-Volumen:

3,597

Relative Volume:

0.03

Marktkapitalisierung:

$6.10M

Einnahmen:

Nettoeinkommen (Verlust:

$-7.50M

KGV:

-0.3247

EPS:

-4.4035

Netto-Cashflow:

$-6.14M

1W Leistung:

+0.00%

1M Leistung:

-7.14%

6M Leistung:

-26.85%

1J Leistung:

-65.87%

1-Tages-Spanne:

$1.4127

$1.42

1-Wochen-Bereich:

$1.39

$1.46

52-Wochen-Spanne:

$1.31

$8.34

Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile

Firmenname

Acurx Pharmaceuticals Inc

Sektor

Healthcare (1087)

Branche

Biotechnology (606)

Telefon

917-533-1469

Adresse

259 LIBERTY AVENUE, STATEN ISLAND

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-14

Neueste SEC-Einreichungen

ACXP's Discussions on Twitter

Compare ACXP vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACXP Acurx Pharmaceuticals Inc	1.42	6.15M	0	-7.50M	-6.14M	-4.4035
VRTX Vertex Pharmaceuticals Inc	522.23	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	800.17	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,000.06	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.44	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.05	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten

Sep 08, 2026

Acurx Pharmaceuticals files prospectus for $1.5 million SEC offering - scanx.trade

Sep 08, 2026

1.5M-share resale puts dilution on table at Acurx (ACXP). How much cash can it still tap? - Stock Titan

Sep 08, 2026

Sep 01, 2026

Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan

Sep 01, 2026

Aug 24, 2026

Acurx (ACXP) Q1 2026 Earnings: Profit Per Share Clears Its Benchmark for the Current Session; After Earnings: The Market Price Moves 1.38% Higher in the Latest ReadingEarnings Call Q&A - vinanet.vn

Aug 24, 2026

Aug 20, 2026

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - The Globe and Mail

Aug 20, 2026

Aug 18, 2026

Acurx (ACXP) Price-Move Recap: Ends Down by 12.73% at $1.44 in the Latest Reading; Key Levels - vinanet.vn

Aug 18, 2026

Aug 17, 2026

Acurx Pharmaceuticals Receives FDA Conditional Acceptance - TradingView

Aug 17, 2026

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - Yahoo Finance

Aug 17, 2026

Aug 15, 2026

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail

Aug 15, 2026

Aug 14, 2026

Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 14, 2026

Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com Nigeria

Aug 14, 2026

Acurx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView

Aug 14, 2026

Acurx Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 3ZO0 | US00510M2035 - marketscreener.com

Aug 14, 2026

Acurx Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | ACXP | US00510M2035 - marketscreener.com

Aug 14, 2026

Acurx Pharmaceuticals Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 14, 2026

Acurx Pharmaceuticals reports Q2 2026 results, advances antibiotic trials, and strengthens patent portfolio. - Pluang

Aug 14, 2026

Acurx Q2 2026 earnings: per-share loss narrows as share count rises - TradingKey

Aug 14, 2026

Acurx Receives Conditional FDA Acceptance for C. difficile Drug Name - Stock Titan

Aug 14, 2026

Aug 13, 2026

ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView

Aug 13, 2026

Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan

Aug 13, 2026

Aug 12, 2026

Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

Aug 12, 2026

New patents cover Acurx antibiotics targeting DNA Polymerase IIIC - Stock Titan

Aug 12, 2026

Aug 10, 2026

Acurx and Leiden Researchers Seek 3D Structure to Guide MRSA Antibiotics - Stock Titan

Aug 10, 2026

Aug 07, 2026

ACXP Q2'26 Earnings: revenue estimate is 0 USD - TradingView

Aug 07, 2026

ACXP Q1 2026 Earnings: Narrower Net Loss Beats Expectations, Shares Rise 4.76%EPS Consistency Score - vinanet.vn

Aug 07, 2026

Aug 05, 2026